Literature DB >> 26329430

Restless Leg Syndrome/Willis-Ekbom Disease Pathophysiology.

Richard P Allen1.   

Abstract

Restless leg syndrome/Willis-Ekbom disease has brain iron deficiency that produces excessive dopamine and known genetic risks, some of which contribute to the brain iron deficiency. Dopamine treatments work temporarily but may eventually produce further postsynaptic down-regulation and worse restless leg syndrome. This article includes sections focused on pathophysiologic findings from each of these areas: genetics, cortical-spinal excitability, and iron and dopamine.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dopamine; Iron; PLMS; RLS augmentation; RLS/WED

Mesh:

Substances:

Year:  2015        PMID: 26329430      PMCID: PMC4559751          DOI: 10.1016/j.jsmc.2015.05.022

Source DB:  PubMed          Journal:  Sleep Med Clin        ISSN: 1556-407X


  62 in total

1.  Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies.

Authors:  N Turjanski; A J Lees; D J Brooks
Journal:  Neurology       Date:  1999-03-23       Impact factor: 9.910

2.  Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding.

Authors:  Simon Cervenka; Sven E Pålhagen; Robert A Comley; Georgios Panagiotidis; Zsolt Cselényi; Julian C Matthews; Robert Y Lai; Christer Halldin; Lars Farde
Journal:  Brain       Date:  2006-07-01       Impact factor: 13.501

3.  Changes of cortical excitability after dopaminergic treatment in restless legs syndrome.

Authors:  Anna Scalise; Italo Pittaro-Cadore; Francesco Janes; Roberto Marinig; Gian Luigi Gigli
Journal:  Sleep Med       Date:  2010-01       Impact factor: 3.492

Review 4.  Distinctive patterns of cortical excitability to transcranial magnetic stimulation in obstructive sleep apnea syndrome, restless legs syndrome, insomnia, and sleep deprivation.

Authors:  Giuseppe Lanza; Mariagiovanna Cantone; Bartolo Lanuzza; Manuela Pennisi; Rita Bella; Giovanni Pennisi; Raffaele Ferri
Journal:  Sleep Med Rev       Date:  2014-04-13       Impact factor: 11.609

5.  Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study.

Authors:  Wolfgang Oertel; Claudia Trenkwalder; Heike Beneš; Luigi Ferini-Strambi; Birgit Högl; Werner Poewe; Karin Stiasny-Kolster; Andreas Fichtner; Erwin Schollmayer; Ralf Kohnen; Diego García-Borreguero
Journal:  Lancet Neurol       Date:  2011-06-24       Impact factor: 44.182

6.  Iron deficiency alters dopamine transporter functioning in rat striatum.

Authors:  K M Erikson; B C Jones; J L Beard
Journal:  J Nutr       Date:  2000-11       Impact factor: 4.798

7.  Peripheral hypoxia in restless legs syndrome (Willis-Ekbom disease).

Authors:  Aaro V Salminen; Ville Rimpilä; Olli Polo
Journal:  Neurology       Date:  2014-04-30       Impact factor: 9.910

8.  Normal dopaminergic and serotonergic metabolites in cerebrospinal fluid and blood of restless legs syndrome patients.

Authors:  Karin Stiasny-Kolster; J Carsten Möller; Johannes Zschocke; Oliver Bandmann; Werner Cassel; Wolfgang H Oertel; Georg F Hoffmann
Journal:  Mov Disord       Date:  2004-02       Impact factor: 10.338

9.  Cerebral white matter alterations in idiopathic restless legs syndrome, as measured by diffusion tensor imaging.

Authors:  Alexander Unrath; Hans-Peter Müller; Albert C Ludolph; Axel Riecker; Jan Kassubek
Journal:  Mov Disord       Date:  2008-07-15       Impact factor: 10.338

10.  T2 relaxometry using 3.0-tesla magnetic resonance imaging of the brain in early- and late-onset restless legs syndrome.

Authors:  Hye-Jin Moon; Yongmin Chang; Yeong Seon Lee; Hee Jin Song; Hyuk Won Chang; Jeonghun Ku; Yong Won Cho
Journal:  J Clin Neurol       Date:  2014-07-03       Impact factor: 3.077

View more
  30 in total

1.  Seeking the Cause of Restless Legs Syndrome in Chronic Kidney Disease.

Authors:  Anne Marie Morse; Sanjeev V Kothare
Journal:  J Clin Sleep Med       Date:  2019-11-15       Impact factor: 4.062

2.  Restless legs syndrome and its variants: a case report.

Authors:  Amée F Wolters; Bart F L van Nuenen
Journal:  Neurol Sci       Date:  2019-11-08       Impact factor: 3.307

Review 3.  Gabapentin treatment in clozapine-induced restless legs syndrome: two cases and a review of the literature.

Authors:  Vijaya Kumar; Ganesan Venkatasubramanian
Journal:  Ther Adv Psychopharmacol       Date:  2016-10-12

Review 4.  Brain imaging and networks in restless legs syndrome.

Authors:  Giovanni Rizzo; Xu Li; Sebastiano Galantucci; Massimo Filippi; Yong Won Cho
Journal:  Sleep Med       Date:  2016-08-29       Impact factor: 3.492

Review 5.  Iron, dopamine, genetics, and hormones in the pathophysiology of restless legs syndrome.

Authors:  Farhan H Khan; Caitlyn D Ahlberg; Christopher A Chow; Divya R Shah; Brian B Koo
Journal:  J Neurol       Date:  2017-02-24       Impact factor: 4.849

Review 6.  Update on Restless Legs Syndrome: from Mechanisms to Treatment.

Authors:  Paulina Gonzalez-Latapi; Roneil Malkani
Journal:  Curr Neurol Neurosci Rep       Date:  2019-06-27       Impact factor: 5.081

Review 7.  Restless Sleep Disorder (RSD): a New Sleep Disorder in Children. A Rapid Review.

Authors:  Lourdes M DelRosso; Maria P Mogavero; Raffaele Ferri; Oliviero Bruni
Journal:  Curr Neurol Neurosci Rep       Date:  2022-06-14       Impact factor: 5.081

Review 8.  Restless Legs Syndrome: Contemporary Diagnosis and Treatment.

Authors:  Thomas R Gossard; Lynn Marie Trotti; Aleksandar Videnovic; Erik K St Louis
Journal:  Neurotherapeutics       Date:  2021-04-20       Impact factor: 7.620

Review 9.  Iron therapy in heart failure patients without anaemia: possible implications for chronic kidney disease patients.

Authors:  Jolanta Malyszko; Stefan D Anker
Journal:  Clin Kidney J       Date:  2017-11-28

10.  Electrophysiological findings of Turkish patients with restless legs syndrome.

Authors:  Ahmet Özsimsek; Hasan Rifat Koyuncuoglu
Journal:  Neuropsychiatr Dis Treat       Date:  2017-07-27       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.